View Older Stories View More Recent Stories

Feb 23, 2021 08:00AM Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors
Feb 19, 2021 08:00AM Intercept to Present at Upcoming Investor Conferences
Feb 17, 2021 08:00AM Intercept Appoints Linda Richardson as Chief Commercial Officer
Feb 16, 2021 05:10PM Greenlight Capital Enters ADT (ADT), EchoStar (SATS), Sonos (SONO) - 13F
Feb 11, 2021 08:00AM Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Jan 27, 2021 01:36PM Intercept Pharma (ICPT) Said Analyst Note Incorrect
Jan 27, 2021 01:35PM Intercept Company Statement on Analyst Note
Jan 11, 2021 08:00AM Intercept Appoints Jared M. Freedberg as General Counsel and Secretary
Jan 5, 2021 08:00AM Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 10, 2020 08:06AM Intercept Pharma (ICPT) Announces Jerry Durso Appointed CEO Effective January 1
Dec 10, 2020 08:00AM Intercept Pharmaceuticals Announces Leadership Transition
Nov 24, 2020 07:00AM Intercept to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 16, 2020 05:03PM Greenlight's 13F shows new stake in NCR Corp (NCR), increase in Atlas Air (AAWW) and Gold ETF (GLD), maintains Tesla (TSLA) short
Nov 16, 2020 08:10AM Intercept Pharma (ICPT) Says New Data from Interim Analysis of REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in Subgroup of High-Risk Patients with Fibrosis Due to NASH
Nov 16, 2020 08:00AM New Data from the Interim Analysis of REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in a Subgroup of High-Risk Patients with Fibrosis Due to NASH
Nov 9, 2020 07:00AM Intercept Pharmaceuticals Reports Third Quarter 2020 Financial Results, Announces Updates to Financial Guidance and Provides Business Update
Nov 2, 2020 04:00PM Intercept to Announce Third Quarter 2020 Financial Results on November 9, 2020
Oct 29, 2020 08:00AM New PBC and NASH Data to be Presented at AASLD’s The Liver Meeting Digital Experience™
Sep 3, 2020 08:00AM Intercept to Present at September Investor Conference
Aug 27, 2020 08:06AM Intercept (ICPT) Announces New Data from Interim Analysis of REGENERATE Show OCA Helped Patients with Liver Fibrosis Due to NASH Achieve Sustained Improvement
Aug 27, 2020 08:00AM New Data from the Interim Analysis of REGENERATE Show that OCA Helped Patients with Liver Fibrosis Due to NASH Achieve Sustained Improvement in Noninvasive Markers of Fibrosis Over Two Years of Treatm
Aug 21, 2020 08:03AM Intercept Pharma (ICPT) to Present New NASH and PBC Data at Digital International Liver Congress 2020
Aug 21, 2020 08:00AM Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2020
Aug 10, 2020 07:00AM Intercept Pharmaceuticals Reports Second Quarter 2020 Financial Results, Announces Updates to Financial Guidance and Provides Business Update
Aug 3, 2020 08:07AM Intercept to Announce Second Quarter 2020 Financial Results on August 10, 2020
Jun 29, 2020 07:00AM Intercept Pharma (ICPT) Receives CRL from FDA for Obeticholic Acid for Treatment of Fibrosis Due to NASH
Jun 29, 2020 07:00AM Intercept Receives Complete Response Letter from FDA for Obeticholic Acid for the Treatment of Fibrosis Due to NASH
May 22, 2020 08:03AM Intercept Pharma (ICPT) OCA AdCom Meeting Postponed
May 22, 2020 08:00AM Intercept Provides Regulatory Update
May 11, 2020 07:00AM Intercept Pharmaceuticals Reports First Quarter 2020 Financial Results, and Provides Business Update
May 6, 2020 08:30AM Intercept to Present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference
Apr 27, 2020 08:00AM Intercept to Announce First Quarter 2020 Financial Results on May 11, 2020
Mar 26, 2020 08:10AM Intercept Pharma (ICPT) announces rescheduling of its advisory committee meeting by FDA
Mar 26, 2020 08:00AM Intercept Pharmaceuticals Provides Regulatory and Business Update
Feb 28, 2020 08:00AM Intercept to Present at the Cowen 40th Annual Health Care Conference
Feb 25, 2020 07:00AM Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Issues 2020 Operating Expense Guidance and Provides Business Update
Feb 18, 2020 08:00AM Intercept to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
Jan 29, 2020 08:09AM Intercept Pharma (ICPT) Reports Complete Enrollment in Phase 3 REVERSE Study Evaluating Obeticholic Acid for Treatment of Compensated Cirrhosis Due to NASH
Jan 29, 2020 08:00AM Intercept Completes Enrollment of Phase 3 REVERSE Study Evaluating Obeticholic Acid for the Treatment of Compensated Cirrhosis due to NASH
Jan 8, 2020 08:00AM Intercept to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 13, 2019 08:05AM Intercept Pharma (ICPT) has submitted MAA to EMA for obeticholic acid for treatment of fibrosis due to NASH
Dec 13, 2019 08:00AM Intercept Provides Regulatory Update
Dec 10, 2019 08:00AM Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York
Dec 6, 2019 06:59AM Intercept Pharma (ICPT) Notes Positive Phase 3 REGENERATE Study of OCA in NASH Published in The Lancet
Dec 5, 2019 07:00PM Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet
Dec 2, 2019 08:00AM Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer
Nov 25, 2019 08:03AM Intercept Pharma (ICPT) NDA for OCA Accepted by FDA, Grants Priority Review
Nov 25, 2019 08:00AM FDA Accepts Intercept’s NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review
Nov 8, 2019 07:18AM Intercept (ICPT) New REGENERATE Interim Analysis Data Presented at AASLD Report OCA Improved Multiple Noninvasive Markers in NASH
Nov 8, 2019 07:00AM New REGENERATE Interim Analysis Data Presented at The Liver Meeting® Report OCA Improved Multiple Noninvasive Markers of Liver Fibrosis in Patients with NASH
View More Recent Stories View Older Stories